Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

Interest Coverage 1.09
NPSP's Interest Coverage is ranked lower than
98% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NPSP: 1.09 )
Ranked among companies with meaningful Interest Coverage only.
NPSP' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.09
Current: 1.09
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

» NPSP's 10-Y Financials

Financials (Next Earnings Date: 0)

Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2014

NPSP Guru Trades in Q2 2014

Eric Mindich 408,141 sh (New)
Louis Moore Bacon 25,000 sh (New)
Joel Greenblatt 12,104 sh (New)
Mariko Gordon 15,986 sh (+7.81%)
Louis Moore Bacon 30,000 sh (unchged)
John Burbank Sold Out
Jim Simons Sold Out
RS Investment Management Sold Out
Pioneer Investments 253,897 sh (-7.42%)
Columbia Wanger 1,736,720 sh (-37.33%)
» More
Q3 2014

NPSP Guru Trades in Q3 2014

Paul Tudor Jones 8,388 sh (New)
Mariko Gordon 16,864 sh (+5.49%)
Pioneer Investments 418,971 sh (unchged)
Louis Moore Bacon Sold Out
Eric Mindich Sold Out
Joel Greenblatt Sold Out
Columbia Wanger 1,257,320 sh (-27.60%)
» More
Q4 2014

NPSP Guru Trades in Q4 2014

Ken Fisher 9,350 sh (New)
Joel Greenblatt 5,743 sh (New)
Pioneer Investments 524,878 sh (+25.28%)
Paul Tudor Jones 10,016 sh (+19.41%)
Mariko Gordon Sold Out
Columbia Wanger 1,217,320 sh (-3.18%)
» More
Q1 2015

NPSP Guru Trades in Q1 2015

Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Pioneer Investments Sold Out
Columbia Wanger Sold Out
Ken Fisher Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NPSP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Traded in other countries:NPM.Germany,

NPS Pharmaceuticals Inc was incorporated in Utah in 1986 and reincorporated in Delaware in 1992. The Company is a biopharmaceutical company, which is focused on the development of new treatment options for patients with rare gastrointestinal and endocrine disorders and serious unmet medical needs. The Company's clinical programs involve two proprietary therapeutic proteins to restore or replace biological function: GATTEX(tm) (teduglutide) and Natpara (parathyroid hormone 1-84 [rDNA origin] injection). GATTEX is its analog of GLP-2, a protein involved in the regeneration and repair of the intestinal lining, and is in Phase 3 clinical development for parenteral dependent (PN) short bowel syndrome (SBS). SBS is a highly disabling condition that results from surgical resection, congenital defect or disease-associated loss of absorption and the subsequent inability to maintain fluid, electrolyte, and nutrient balances on a conventional diet. Natpara is the Company's recombinant full-length human parathyroid hormone (PTH 1-84) that is in Phase 3 clinical development for hypoparathyroidism, a rare condition in which the body does not maintain normal calcium levels in the blood due to insufficient levels of parathyroid hormone. The Company is currently advancing registration studies for GATTEX and Natpara. The Company has collaborations or royalty agreements with a number of pharmaceutical companies. 'NPS, 'NPS Pharmaceuticals', 'GATTEX', and 'PREOS' are the Company's trademarks. The Company has competitors in both the U.S. and internationally including multi-national pharmaceutical companies, chemical companies, biotech companies, universities and other research organizations. Many of its competitors have drug products that have already been approved or are in development, and operate large, well-funded research and development programs in these fields.



Buy Back


Valuation & Return


More Statistics

Revenue (TTM) (Mil) $211.8
EPS (TTM) $ 0.02
Short Percentage of Float5.50%
52-Week Range $22.11 - 46.01
Shares Outstanding (Mil)106.84

Analyst Estimate

Dec14 Dec15 Dec16 Dec17
Revenue (Mil $) 227 420 614 839
EPS ($) 0.01 1.06 2.17 2.76
EPS w/o NRI ($) 0.01 1.06 2.17 2.76
EPS Growth Rate
(3Y to 5Y Estimate)
Dividends Per Share ($)
» More Articles for NPSP


Articles On GuruFocus.com
Wedbush Weighs in on Medivation Following Phase II TERRAIN Study Results Feb 03 2015 
Shire Set To Acquire NPS Pharmaceuticals for $5.2 Billion Jan 15 2015 
Weekly CFO Sells Highlight: WRES, NPSP, MKTO, GRPN, RXN Sep 29 2013 
Weekly CFO Sells Highlight: KO, KKD, PIR, NPSP, ACAD Apr 16 2013 
NPS Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2009 
George Soros Buys Partner Communications Co. Ltd, CR Bard Inc., Valley Forge Scientific Corp., Sells Aug 15 2006 

More From Other Websites
How Has Shire Benefited from NPS Pharmaceuticals Acquisition? Apr 11 2016
Shire confident on 2015 after NPS deal, binge-eating drug approval Feb 12 2015
Shire sees mid-single earnings growth in 2015 Feb 12 2015
U.S. FDA approves NPS drug, in move validating Shire takeover deal Jan 23 2015
FDA approves NPS drug, in move validating Shire takeover deal Jan 23 2015
[video]Jim Cramer's 'Mad Money' Recap: Blame Tech, Oil and Retail for Today's Losses Jan 12 2015
Cramer: Hold Your Fire Jan 12 2015
Cramer: Hold Your Fire Jan 12 2015
Cramer: Hold Your Fire Jan 12 2015
Shire to buy NPS for $5.2 billion to boost rare disease drugs Jan 11 2015
Shire to buy NPS for $5.2 bln to boost rare disease drugs Jan 11 2015
Shire to buy specialty drugmaker NPS Pharma for $5.2 billion Jan 11 2015
Shire considering bid for NPS Pharmaceuticals - Bloomberg Dec 17 2014
NPS reports 3Q loss Nov 10 2014
NPS Pharma says FDA extends review of Natpara Oct 23 2014
Merrill Lynch’s 5 Destroyed Biotech Stocks With 100% or More Upside Potential Oct 20 2014
NPS Pharma Enters Cautionary Phase of the FDA Approval Process Sep 15 2014
U.S. FDA panel recommends approval of NPS hormone replacement drug Sep 12 2014
Does New Data Make or Break NPS Pharmaceuticals? Sep 10 2014
FDA staff: NPS drug effective; no significant safety imbalance Sep 10 2014
PRESS DIGEST-Sunday British Business-June 29 Jun 29 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)